Section
Markets
Earnings, deals, financings and the public companies behind peptides.
- 09:34Fitt Insider
Power Plate Launches RESET Collection Aimed at GLP-1 Medication Users
By Tom Reyes - 09:30EIN News
GLP-1 Companion Food Market Forecast to Hit $11.66 Billion by 2030
By Tom Reyes - 09:01Precedence Research
Precedence Research Publishes Semaglutide Market Outlook Through 2035
By Tom Reyes - 08:58PEPTI
PEPTI stays in compounded GLP-1s as larger platforms step back
By Tom Reyes - 08:58PEPTI
PEPTI charges no membership fee as rivals stack monthly dues
By Tom Reyes - 07:00finance.yahoo.com
Novo Nordisk signs Orbis Medicines discovery deal worth up to $1.4 billion
By Tom Reyes - 04:50ad-hoc-news.de
Novo Nordisk trims pipeline and rebrands amid obesity competition
By Tom Reyes - 02:13finance.yahoo.com
Cracker Barrel Falls 15.5% as GLP-1 Shift Hits Traffic
By Tom Reyes - Sep 16PlexusDx
PlexusDx Details Cora Health Semaglutide Plan Costs and Fees
By Tom Reyes - Sep 16PlexusDx
PlexusDx Compares Cheaper GLP-1 Providers Against Cora Health
By Tom Reyes - Sep 16PlexusDx
PlexusDx Compares Seven GLP-1 Providers Against Trava Pricing
By Tom Reyes - Sep 16PlexusDx
PlexusDx Outlines Cora Health Tirzepatide Pricing for 2026
By Tom Reyes - Sep 16PlexusDx
PlexusDx Asks Whether Lavender Sky GLP-1 Costs Rise With Dose
By Tom Reyes - Sep 16PlexusDx
PlexusDx Reviews Brello Health GLP-1 Dose-Based Pricing
By Tom Reyes - Sep 16USA Today
PLU Laboratories Pledges Transparency Push for GHK-Cu Peptide Cosmetics
By Tom Reyes - Sep 16Employee Benefit News
Benefits advisers outline considerations for employer GLP-1 coverage decisions
By Tom Reyes - Sep 16simplywall.st
Analysis argues Novo Nordisk shares trade 59% below fair value
By Tom Reyes - Sep 16Stocktwits
Novo Nordisk stock posts worst week since February amid rebrand
By Tom Reyes - Sep 16Seeking Alpha
Analyst says Novo rebrand signals strategy shift, not just marketing
By Tom Reyes - Sep 16simplywall.st
Novo Nordisk Turns to AI to Reshape Drug Discovery
By Tom Reyes - Sep 16Sacramento Bee
Sacramento Restaurant Adapts Menu as GLP-1 Use Curbs Appetites
By Tom Reyes - Sep 16PR Newswire
Veritiv Launches TempSafe RxShield for GLP-1 Cold-Chain Shipping
By Tom Reyes
- Sep 16Nutrition Insight
Lactalis Ingredients Targets Protein Bar Texture as GLP-1 Shifts Demand
By Tom Reyes Pharmacy leader urges linking GLP-1 coverage to wellness program participation
By Tom Reyes- Sep 16Currently.com
Analysts weigh Novo Nordisk's position as GLP-1 competition intensifies
By Tom Reyes - Sep 16The Washington Post
Washington Post: GLP-1 weight-loss coverage may tighten for patients
By Tom Reyes - Sep 16Seeking Alpha
Haleon US sales rise as company markets GLP-1 side-effect remedies
By Tom Reyes - Sep 16TradingKey
Eli Lilly shares rise 3.2% to $1,139 in market quote
By Tom Reyes - Sep 16ad-hoc-news.de
Novo Nordisk shares slip after rebrand to Novo draws analyst caution
By Tom Reyes - Sep 15NAI500
Eli Lilly accelerates acquisitions to diversify beyond weight-loss franchise
By Tom Reyes - Sep 15PlexusDx
Telehealth Provider Levity Details Semaglutide Plan and Renewal Pricing
By Tom Reyes - Sep 15PlexusDx
Levity Prices Branded Mounjaro Tirzepatide at $1,299 Monthly
By Tom Reyes - Sep 15simplywall.st
Novo Nordisk Rebrands as Novo, Resets Corporate Operating Model
By Tom Reyes Navitus Launches GLP-1 Drug Management Programs for Payers
By Tom Reyes- Sep 15ad-hoc-news.de
Novo Nordisk Shares Fall After Rebrand Meets Investor Skepticism
By Tom Reyes - Sep 15finance.yahoo.com
Berenberg sees 21% upside in Lilly ahead of EASD data
By Tom Reyes - Sep 15finance.yahoo.com
Analysts weigh Novo Nordisk against Regeneron for 2026 investors
By Tom Reyes - Sep 15CNBC
Berenberg says Mounjaro maker Lilly has further upside
By Tom Reyes - Sep 15TipRanks
Ascendis regains full rights to TransCon metabolic programs from Novo
By Tom Reyes - Sep 14simplywall.st
Analysis Examines Novo Nordisk's Pivot Toward Obesity Market
By Tom Reyes - Sep 14Quiver Quantitative
Ascendis Pharma Regains Rights to TransCon Semaglutide Program
By Tom Reyes - Sep 14Yellow.com
Bitcoin payments fuel $32M gray-market peptide trade
By Tom Reyes - Sep 14Seoul Economic Daily
Samik Pharm jumps 16% on monthly thymosin alpha 1 patent
By Tom Reyes - Sep 12Stocktwits
Hims & Hers leans on testosterone as GLP-1 competition intensifies
By Tom Reyes